newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Full year fiscal 2025 net revenue of $66.4 millionFull year fiscal 2025 net loss of $13.6 millionFull year fiscal 2025 adjusted EBITDA1 of $9.2 million$31.0 million cash balance at June 30, 2025Exclusive agreement in